Life-saving
heart attack prevention

Improve patient outcomes with precision coronary imaging to detect high-risk vulnerable plaques.

Octiocor hero image

Accurate, Consistent and Cost Effective.

Mission

Our mission is to prevent heart attacks in high-risk patients through our revolutionary coronary imaging technology.

We aim at providing the best intracoronary imaging (ICI) analysis software.

Offering cutting-edge intracoronary imaging analysis software, our platform is at the forefront of cardiovascular care, dedicated to studying and ultimately preventing heart attacks, in high-risk patients.

Our AI-based software empowers clinicians with comprehensive tools for in-depth analysis, facilitating proactive interventions and personalized treatments that prioritize the long-term well-being of high-risk individuals.

AI-driven technology

We use Optical Coherence Tomography (OCT) images — the highest resolution in-vivo modality — to study atherosclerosis, the disease causing most heart attacks and strokes.

AutoOCT™, our AI-based software, corrects for frequent image artifacts, identifies accurately demarcated tissue interfaces, and measures clinically important lumen and plaque parameters.

Real-time tissue segmentation and measurement identify high-risk vulnerable plaques, guiding evidence-based prophylactic treatment of high-risk patients that improves outcomes.

AutoOCT™ can also be used for clinical trials and research analysis.

Future development will include IVUS and hybrid imaging.

001

OCT Image

Octiocor hero image

002

AutoOCT™ Segmentation

Octiocor hero image

003

AutoOCT™ Stress Map

Octiocor hero image
Octiocor hero image

Lipid

Octiocor hero image

Lumen

Octiocor hero image

Calcium

Octiocor hero image

Thin Fibrous Cap

AI-driven

Leverages a series of deep-learning AI modules to identify, segment and measure different tissue structures in intracoronary OCT images.

Consistent and repeatable

Eliminates well-documented human inter-observer variability when reading OCT images.

Large curated dataset

Trained on the largest known curated dataset of diverse and unselected patients with early and advanced disease states.

Fast and cost effective

Delivers analysis via web interface to clinical trials sponsors in minutes rather than waiting months for human annotation.

0:00   |    0:00

Applications

The AutoOCT™ AI engine segments and measures relevant clinical parameters on all frames in a pullback in real time, including lumen diameters and area, and demarcates the external elastic lamina (EEL). Importantly, AutoOCT™ accurately measures lipid and calcium arc, depth and area, Fibrous Cap Thickness (FCT), and plaque structural stress (PSS), all important features of high risk vulnerable plaques. AutoOCT™ comprehensive output can provide timely information to the cardiologist to guide interventional procedures.

The AutoOCT™ AI engine is the intelligent add-on to any ICI medical device for real time image interpretation and clinical decision support in interventional cardiology.

Octiocor hero image

The AutoOCT™ web-based platform enables data aggregation from different clinical sites where patient pullback images are captured in a secure and timely fashion, protecting patient data confidentiality and streamlining the clinical trial workflow. Once uploaded, each pullback image is analysed with our cutting-edge AI tissue segmenter and required clinical measurements are extracted. Tissue segments and measurements can be visualised immediately on the web-platform. The clinical measurements can be downloaded in a excel or CSV format for subsequent cohort analysis.

The AutoOCT™ web-based platform is the ideal companion for clinical trials and research in the study coronary disease applications for medtech/drug companies, core laboratories and academic researchers.

Octiocor hero image

Our latest news

1 min read   |   January 30, 2026

Octiocor blog image.

Octicor appoints Natalie Hayes as CEO

Octiocor Appoints Dr Natalie Hayes as Chief Executive Officer Cambridge, UK

Octiocor Limited, a University of Cambridge spin-out developing novel AI-based Cardiology imaging technology, has appointed Dr Natalie Hayes as Chief Executive Officer.

Dr Hayes is dually qualified in medicine and law, with over 20 years of leadership experience across clinical practice, medical device development, regulation, and healthcare innovation in the UK, EU, MEA, and North America. She has led regulatory, clinical, and corporate affairs functions at both high growth Medtech start-ups and established international manufacturers, bringing deep expertise in clinical strategy and commercial execution, alongside a strong track record of translating complex clinical evidence into successful commercial outcomes. Most recently, Dr Hayes served as Senior Vice President of Clinical, Regulatory and Corporate Affairs and Board Director at Lombard Medical, where she played a key role in the company’s acquisition by MicroPort Endovastec, led global regulatory and clinical strategy for Class III implantable devices, and oversaw international clinical programmes supporting regulatory approvals and market expansion.

Commenting on her appointment, Dr Hayes said: “As a long-term resident of Cambridge, I am very excited to be working with Octiocor, a fabulous University of Cambridge company, which has been built and supported by an incredibly talented team to address a clear unmet clinical need in the care of cardiology patients.”

Hayley French, Chair of Octiocor, added: “Natalie’s appointment represents a pivotal step in translating Octiocor’s pioneering research into meaningful clinical and commercial outcomes. Her rare combination of medical, legal, and regulatory expertise positions us to accelerate innovation, attract strategic investment, and bring transformative imaging technology from Cambridge to patients globally.”

The appointment strengthens Octiocor’s leadership team as the company progresses its technology through advanced development and prepares for important clinical and regulatory milestones.

About Octiocor Limited Octiocor Limited is a University of Cambridge spin-out medical device company developing a novel cardiology imaging technology designed to address significant unmet clinical needs in cardiovascular care.

Enquiries: Natalie Hayes Octiocor Limited info@octiocor.com

Read full article

2 min read   |   March 19, 2025

Octiocor blog image.

AI Image Analysis Co-founders’ Publication Accepted by European Heart Journal Digital Health

In a major step forward for both AI and cardiovascular medicine, the European Heart Journal Digital Health has accepted a comprehensive review by Octiocor Ltd founders Prof. Martin Bennett and Dr. Mike Roberts on the role of artificial intelligence in intracoronary optical coherence tomography (OCT).

Intracoronary OCT is a high-resolution imaging technique that captures detailed views of the coronary arteries, enabling early diagnosis of cardiovascular disease. However, interpreting OCT data remains complex and time-consuming, making it an ideal candidate for AI innovation.

The review examines the current academic publication landscape for AI applications in OCT, spotlighting how machine learning is transforming image analysis, enhancing diagnostic accuracy, and predicting patient outcomes with increasing speed and precision. It also addresses key challenges, including data variability, model generalisability, and regulatory barriers.

“AI holds great potential to dramatically improve diagnostic accuracy in many fields, including cardiovascular imaging,” said Dr. Mike Roberts. “Our review offers a clear snapshot of current capabilities and outlines where we need to go next.”

The publication underscores Octiocor’s leadership at the intersection of AI and cardiovascular imaging—two fields poised for rapid transformation.

“This review is just the beginning,” added Prof. Martin Bennett. “We’re committed to advancing AI tools that can truly make a difference in clinical care.”

Stay tuned for more from Octiocor as they continue to push the boundaries of medical imaging through AI.

Read full article

1 min read   |   February 11, 2025

Octiocor blog image.

Octiocor’s AutoOCT™ Selected for Oral Presentation at EuroPCR 2025

We’re excited to share that Octiocor’s groundbreaking automated OCT analysis system, AutoOCT™, has been selected for two oral presentations at EuroPCR 2025, Europe’s premier event for interventional cardiovascular medicine, including the prestigious Innovations session. EuroPCR brings together leading experts in cardiology and provides a powerful platform to showcase advancements that could shape the future of cardiovascular care.

The opportunity to present AutoOCT™ at EuroPCR is a significant milestone for Octiocor, as it underscores the growing recognition of our system’s potential to transform the field of cardiac imaging. AutoOCT™ woffers clinicians a faster, more accurate, and repeatable way to analyse OCT images, empowering them to make critical decisions with greater confidence.

We’re looking forward to the engaging discussions and feedback from thought leaders in the cardiovascular community. This recognition is not just a testament to the hard work of our team but also to the incredible promise of AutoOCT™ in improving patient care and advancing the future of interventional cardiology. Stay tuned for more exciting updates as we prepare for this incredible opportunity!

Read full article

1 min read   |   October 7, 2024

Octiocor blog image.

Octiocor’s AutoOCT™ Shines at 2024 TCT Meeting in Washington D.C.

Octiocor is proud to announce that our cutting-edge automated OCT analysis system, AutoOCT™, was featured in the Innovations session at the prestigious 2024 International Transcatheter Therapeutics (TCT) meeting in Washington D.C. TCT is one of the most influential global forums for interventional cardiology, bringing together experts and innovators from across the world.

During the event, Octiocor co-founder and CMO Prof. Martin Bennett shared insights on the powerful capabilities of AutoOCT™, which will revolutionise the way clinicians analyse optical coherence tomography (OCT) images. As Martin Bennett said ‘We had a great response from both industry and potential funders that we’re currently exploring’, and Octiocor is currently exploring exciting opportunities to advance AutoOCT™ further, thanks to the invaluable connections made at TCT.

At Octiocor, we're committed to improving patient outcomes and advancing medical technology. With AutoOCT™, we’re making significant strides toward providing faster, more accurate diagnostic tools for cardiologists worldwide. Stay tuned for more updates as we continue to innovate and lead the way in cardiac imaging.

Read full article